Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

Completed

• Conditions: Premature Birth; Necrotizing Enterocolitis

• Registration Number: NCT00059449
• Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Brief Summary

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-04-25
• Study First Submitted QC: 2003-04-28
• Study First Posted: 2003-04-29
• Status Verified: 2010-01
• Last Update Submitted: 2010-01-12
• Last Update Posted: 2010-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 372

Inclusion Criteria

• Gestational Age greater than 23 weeks at birth
• Birth weight greater than 500 grams
• Age less than 72 hours of life

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (3)

University Hospital; 🇺🇸 Cincinnati, Ohio, United States

Good Samaritan Hospital; 🇺🇸 Cincinnati, Ohio, United States

Cincinnati Children's Hospital Medical Center; 🇺🇸 Cincinnati, Ohio, United States